首页 | 本学科首页   官方微博 | 高级检索  
     检索      

瑞舒伐他汀与替格瑞洛联合用药方案治疗非ST段抬高型急性冠脉综合征患者的临床效果及不良反应
引用本文:江洋.瑞舒伐他汀与替格瑞洛联合用药方案治疗非ST段抬高型急性冠脉综合征患者的临床效果及不良反应[J].中国药物经济学,2020(3):76-78,82.
作者姓名:江洋
作者单位:沈阳积水潭医院药学部
摘    要:目的探讨瑞舒伐他汀与替格瑞洛联合用药方案治疗非ST段抬高型急性冠脉综合征(ACS)患者的临床效果及不良反应。方法选取2018年1月至2019年7月沈阳积水潭医院收治的70例非ST段抬高型ACS患者作为研究对象,依据随机数字表法分为对照组和观察组,每组35例。对照组采用替格瑞洛治疗,观察组采用瑞舒伐他汀与替格瑞洛联合用药方案治疗,比较两组临床疗效、心肌损伤指标、炎症介质水平、不良反应发生率。结果观察组治疗有效率高于对照组,差异有统计学意义(P<0.05);观察组肌酸激酶同工酶、肌钙蛋白水平低于对照组,差异有统计学意义(P<0.05);观察组炎症介质水平、不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀与替格瑞洛联合用药方案治疗非ST段抬高型ACS临床效果显著,不仅可以改善临床相关指标、心肌损伤,还可减轻炎症反应,且不良反应发生率低。

关 键 词:非ST段抬高型  急性冠脉综合征  瑞舒伐他汀  替格瑞洛  联合用药方案  临床效果  不良反应

Clinical Effects and Adverse Reactions of Rosuvastatin Combined with Tegrarol in the Treatment of Patients with Non-ST Elevation Acute Coronary Syndrome
JIANG Yang.Clinical Effects and Adverse Reactions of Rosuvastatin Combined with Tegrarol in the Treatment of Patients with Non-ST Elevation Acute Coronary Syndrome[J].China Journal of Pharmaceutical Economics,2020(3):76-78,82.
Authors:JIANG Yang
Institution:(Department of Pharmacy,Shenyang Jishuitan Hospital,Shenyang 110141,China)
Abstract:Objective To explore the clinical effects and adverse reactions of rosuvastatin combined with tegrarol in the treatment of patients with non-ST elevation acute coronary syndrome(ACS).Methods A total of 70 patients with non ST-elevation ACS admitted to Shenyang Jishuitan Hospital from January 2018 to July 2019 were selected as the study objects.According to the random number table method,the study objects were divided into a control group and an observation group(with 35 cases in each group).The control group was treated with tegrarol,and the observation group was treated with rosuvastatin and tegrarol.The clinical indexes,myocardial injury indexes,levels of inflammatory factors and the incidence of adverse reactions were compared between the 2 groups.Results The total effective rate of the observation group was higher than that in the control group,with statistical significance(P<0.05).The levels of creatine kinase isoenzyme and troponin in the observation group were lower than those in the control group,with statistical significance(P<0.05);the levels of inflammatory factors and adverse reactions in the observation group were lower than those in the control group,with statistical significance(P<0.05).Conclusion The combination of rosuvastatin and tegrarol in the treatment of non-ST elevation of patients with ACS has a significant clinical effects.It can not only improve the clinical related indexes,myocardial injury indexes,but also alleviate the level of inflammatory factors,and the incidence of adverse reactions is low.
Keywords:Non-ST elevation  Acute coronary syndrome  Rosuvastatin  Tegrarol  Combination therapy  Clinical effects  Adverse reactions
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号